Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Baluretgene parvec by Ocugen for Leber Congenital Amaurosis (LCA): Likelihood of Approval
Baluretgene parvec is under clinical development by Ocugen and currently in Phase III for Leber Congenital Amaurosis (LCA). According to...
Data Insights
Baluretgene parvec by Ocugen for Retinitis Pigmentosa (Retinitis): Likelihood of Approval
Baluretgene parvec is under clinical development by Ocugen and currently in Phase III for Retinitis Pigmentosa (Retinitis). According to GlobalData,...